Gu Xiaojing, Su Yun-Ai, Lin Jingyu, Chen Xiaowei, Bushnell Donald M, Fu Dongjing, Jamieson Carol, Rozjabek Heather, Si Tianmei
Johnson & Johnson Innovative Medicine, Shanghai, China.
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
Gen Psychiatr. 2025 Apr 3;38(2):e101789. doi: 10.1136/gpsych-2024-101789. eCollection 2025.
The patient-reported Dimensional Anhedonia Rating Scale (DARS) has been adapted into Chinese, so there is a need to evaluate its measurement properties in a Chinese population.
To evaluate the reliability and validity of the DARS among Chinese individuals with major depressive disorder (MDD) and its treatment sensitivity in a prospective clinical study.
Data were from a multicentre, prospective clinical study (NCT03294525), which recruited both patients with MDD, who were followed for 8 weeks, and healthy controls (HCs), assessed at baseline only. The analysis included confirmatory factor analysis, validity and sensitivity to change.
Patients' mean (standard deviation (SD)) age was 34.8 (11.0) years, with 68.7% being female. 75.2% of patients with MDD had melancholic features, followed by 63.8% with anxious distress. Patients had experienced MDD for a mean (SD) of 9.2 (18) months. DARS scores covered the full range of severity with no major floor or ceiling effects. Confirmatory factor analysis showed adequate fit statistics (comparative fit index 0.976, goodness-of-fit index 0.935 and root mean square error of approximation 0.055). Convergent validity with anhedonia-related measures was confirmed. While the correlation between the DARS and the Hamilton Depression Rating Scale was not strong (r=0.31, baseline), the DARS was found to differentiate between levels of depression. Greater improvements in DARS scores were seen with the Hamilton Rating Scale for Depression responder group (effect size 1.16) compared with the non-responder group (effect size 0.46).
This study comprehensively evaluated the measurement properties of the DARS using a Chinese population with MDD. Overall, the Chinese version of DARS demonstrates good psychometric properties and has been found to be responsive to change during antidepressant treatment. The DARS is a suitable scale for assessing patient-reported anhedonia in future clinical trials.
患者报告的维度性快感缺乏评定量表（DARS）已被翻译成中文，因此有必要在中国人群中评估其测量属性。
在一项前瞻性临床研究中，评估DARS在中国重度抑郁症（MDD）患者中的信度和效度及其治疗敏感性。
数据来自一项多中心前瞻性临床研究（NCT03294525），该研究招募了MDD患者（随访8周）和健康对照者（仅在基线时进行评估）。分析包括验证性因子分析、效度和变化敏感性。
患者的平均（标准差）年龄为34.8（11.0）岁，68.7%为女性。75.2%的MDD患者有抑郁特征，其次是63.8%有焦虑痛苦症状。患者经历MDD的平均（标准差）时间为9.2（18）个月。DARS评分涵盖了所有严重程度范围，没有明显的地板效应或天花板效应。验证性因子分析显示拟合统计量良好（比较拟合指数0.976，拟合优度指数0.935，近似均方根误差0.055）。与快感缺乏相关测量的收敛效度得到证实。虽然DARS与汉密尔顿抑郁评定量表之间的相关性不强（r = 0.31，基线），但发现DARS能够区分抑郁水平。与未缓解组（效应量0.46）相比，汉密尔顿抑郁评定量表缓解组的DARS评分改善更大（效应量1.16）。
本研究使用中国MDD患者群体全面评估了DARS的测量属性。总体而言，中文版DARS显示出良好的心理测量属性，并且在抗抑郁治疗期间对变化有反应。DARS是未来临床试验中评估患者报告的快感缺乏的合适量表。
